Related references
Note: Only part of the references are listed.Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
Harvey D. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Disposition and Metabolism of Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Humans
Mehul Dave et al.
DRUG METABOLISM AND DISPOSITION (2014)
Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events
Dylan L. Steen et al.
CARDIOLOGY AND THERAPY (2013)
The Role of Lipoprotein-Associated Phospholipase A2 (Lp-PLA(2)) in Cardiovascular Disease
Ignatios Ikonomidis et al.
REVIEWS ON RECENT CLINICAL TRIALS (2011)
Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque
Patrick W. Serruys et al.
CIRCULATION (2008)
A review and assessment of potential sources of ethnic differences in drug responsiveness
TD Bjornsson et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Share Paper
